Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.

Emibetuzumab (LY2875358) inhibits HGF-stimulated proliferation of H596 at a concentration of 100 nmol/L for 6 days[1].

Emibetuzumab (LY2875358) exhibits antitumor effects on MET-amplified xenograft mouse tumor models. It inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice at a dose of 10 mg/kg via intravenous administration once a week for 5 weeks. Additionally, a single intravenous dose of 10 or 20 mg/kg results in the downregulation of MET and pMET levels in the tumors of mice. The antitumor effects persist when administered once a week for 3, 5, or 6 weeks at a dose of 10 mg/kg[1].